Year: 2013

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (December 30, 2013) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has closed its previously announced non-brokered private placement of units, … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO – (December 12, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces its intention to complete a non-brokered private placement of … Continued

TORONTO, ONTARIO – (November 7, 2013) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is proud to announce that Dr. John Wallace, the Corporation’s Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today. This prestigious award, named after Corneille Heymans, a 1938 Nobel Prize winner for … Continued

TORONTO, ONTARIO – (October 22, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) today granted its independent directors and a new addition to its management team options to purchase a total of 250,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option bares an exercise price of $0.55, … Continued

TORONTO, ONTARIO – (October 4, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on September 30, 2013. The matters voted upon at the meeting and the results of the … Continued

TORONTO, ONTARIO – (August 30, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSX VENTURE: ATE) announced today that Walt Macnee has been appointed as Chairman of the Board of Directors of the Corporation to replace John Wallace, who will continue to serve as a director and Chief Science Officer. Mr. Macnee’s appointment was … Continued

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS TORONTO, ONTARIO – (August 22, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSX VENTURE: ATE) is pleased to announce that on August 22, 2013 … Continued